ArticleJournal of pain research2026
Esketamine as an Adjuvant to Levobupivacaine in Thoracic Paravertebral Block for Thoracoscopic Lung Cancer Surgery: A Retrospective Propensity Score-Matched Cohort Study.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective, propensity score-matched cohort study evaluated postoperative analgesic, recovery, and safety outcomes associated with esketamine added to levobupivacaine for thoracic paravertebral block after thoracoscopic lung cancer surgery. Methods: We analyzed patients undergoing thoracoscopic resection of non-small cell lung cancer between January 2020 and December 2024. Of 412 patients screened, 374 entered 1:1 propensity score matching. The esketamine group received 20 mL of 0.375% levobupivacaine with esketamine (0.5 mg/kg), whereas controls received levobupivacaine alone. The co-primary outcomes were 48-hour cumulative sufentanil consumption and postoperative pain intensity assessed by visual analog scale scores at 6, 24, and 48 hours. Secondary outcomes were time to first ambulation, chest tube duration, and hospital stay. Calendar-year-adjusted regression and a contemporaneous 2022-2024 analysis assessed sensitivity to temporal differences. Results: After matching, 328 patients (164 per group) were analyzed. Mean 48-hour sufentanil consumption was 30.2% lower with esketamine (55.2 ± 11.9 μg vs 79.1 ± 12.8 μg; P < 0.001), and pain scores at rest and during coughing were lower at all assessed times (all P < 0.001). Recorded times to first ambulation, chest tube removal, and discharge were shorter (all P < 0.001). The estimated association with sufentanil consumption was materially unchanged after calendar-year adjustment (β = -24.2 μg; 95% CI, -27.1 to -21.2) and in the contemporaneous subset (β = -24.3 μg; 95% CI, -27.6 to -21.0). Psychomimetic events occurred in 14/164 esketamine recipients (8.5%) and no controls. Conclusion: Esketamine added to levobupivacaine for thoracic paravertebral block was associated with lower postoperative opioid consumption and pain scores and shorter recorded times to recovery milestones. However, residual confounding cannot be excluded, and the 8.5% psychomimetic event rate does not support routine adoption of the 0.5 mg/kg regimen. Prospective randomized dose-finding trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.